Laboratory of Virology and Infectious Disease

▲TOP

Basic Information

Ju-Chien Cheng, PhD (鄭如茜博士)
Professor

Associate Professor Department of Medical Laboratory Science and Biotechnology, China Medical University
Email: jccheng@mail.cmu.edu.tw
Phone: 886-4-22053366 ext. 7208 
Fax: 886-4-22022073
Office: 14 F, Li-Fu Teaching Building
Mailing Address: Department of Medical Laboratory Science and Biotechnology, China Medical University
91, Hsueh-Shih Rd., Taichung, Taiwan 40402, R.O.C.

 

Education

Institution Nation Department/Program Degree Dates
National Taiwan University Taiwan, ROC Graduate Institute of Microbiology PhD From 1992 / 9 to 2000 / 1
Fu Jen Catholic University Taiwan, ROC Graduate Institute of Biology Master From 1988 / 9 to 1990 / 7
China Medical College Taiwan, ROC Medical Technology Bachelor From 1984 / 9to 1988 / 6

 

Current Position

Institution Department/Program Position Duration
China Medical University     From 2012 / 08  to Now
Taiwan Society of Laboratory Medicine. Journal of Biomedical and Laboratory Sciences Editor From 2009 / 10  to Now

 

Professional Experience

Institution Department/Program Position Duration
China Medical University Department of Medical Laboratory Science and Biotechnology Associate Professor From 2000 / 08  to 2013
Chaoyang University of Technology Graduate Institute of Biotechnology Adjunct Associate Professor From 2005 / 08  to 2011/06
China Medical University Hospital Department of Laboratory Medicine Consultant From 2003 / 08  to 2010
From 2013 / 08  to 2014
China Medical University Office of Research and Development/ Division of Academic Development Leader From 2005 / 08 to 2006 /02
China Medical College Department of Medical Technology Chairman From 2000 / 08 to 2003 / 07
The Association of Laboratory Medicine Bulletin of The Association of Laboratory Medicine Editor From 2001 / 01 to 2003 / 12
China Medical College Department of Medical Technology Instructor From 1990 / 08 to 2000 / 06

 

▲TOP

Research

Our recent works mainly focus on understanding the molecular mechanism underlying hepatitis C virus (HCV) virus-host interaction and finding natural products with anti-viral activity against HCV. In addition, we are also interested in the development of innovative molecular diagnostics technology for detection of viral and bacterial infection. Our major research accomplishments are briefly summarized in the following section.

Defining the roles of virus-host interactions in HCV pathogenesis
During the last five years, several research platforms for investigation of HCV were established and performed well in our laboratory including HCV replicon cells, HCV pseudotyped virus (HCVpv), HCV cell cultured virus system (HCVcc) and activity assays for HCV viral protease, helicase and RdRp. With these research tools, we have defined several important host factors that play roles in the HCV pathogenic process. At first, to understand the molecular mechanisms that underlying HCV replication, we focus our study on NS5B RNA polymerase to elucidate how NS5B interacts with host proteins to regulate viral replication and pathogenesis. The cellular protein fatty acid synthase (FASN) was identified in our laboratory to interact with NS5B by coimmunoprecipitation and double staining assays. Furthermore, the interacting domain between NS5B and FASN was mapped. In addition, FASN is associated with detergent-resistant lipid rafts and is colocalized with NS5B in active HCV replication complexes. Notably, FASN plays important roles in HCV replication by increasing HCV NS5B RdRp activity in vitro. Our data indicate that FASN may serve as a target for the treatment of HCV infection and the prevention of HCV-associated HCC progression. These results have been published recently in the prestigious journal in the field of virology (J Virol. 87:4994-5004, 2013).

In addition to the cellular proteins, the non-coding microRNA (miRNA) has been shown to involve in the regulation of viral infection and offers an alternative target for developing anti-viral agent. Using bioinformatic analyses, a novel cellular miRNA let-7b was predicted as a liver-abundant miRNA that can target all 6 genotypes of HCV genome. Several HCV cell-based assays were performed to demonstrate that let-7b suppresses HCV RNA accumulation leading to reduced infectivity of HCVcc. These data provide strong evidence to support our bioinformatics predictive outcome and implicate that let-7b is a negative regulator of HCV infection. Mutational analysis identified let-7b binding sites at the coding sequences of NS5B and 5’-UTR of HCV genome. In addition, let-7b-mediated suppression of HCV RNA accumulation was not dependent on inhibition of HCV translation. Furthermore, let-7b and IFNα-2a elicited synergistic inhibitory effect on HCV infection. Our data indicated that let-7b represents a novel cellular miRNA that targets on HCV genome and elicits anti-HCV activity (Cell Mol Life Sci. 69:2621-33, 2012). Moreover, working with the clinicians, we found that pre-therapeutic and interferon-induced hepatic expressions of MxA and OAS1 in an ex vivo assay independently predict treatment outcomes in chronic hepatitis C (J Viral Hepat. 19:e154-62, 2012). Interestingly, let-7b can be induced during HCV infection and upregulates MxA and OAS1 expression. The data was presented in the 21th International Symposium on Hepatitis C Virus& Related Viruses (Banff, Canada, 2014).

By using the serum-derived HCV, HCVpv and J6JFH based HCVcc systems, we also demonstrate that the cell entry but not the RNA replication is enhanced by co-expression of CD81 and aci-reductone dioxygenase 1 (ADI1) (J Med Virol. 81:1560-1568, 2009). The human ADI1 gene is a member of the Cupin superfamily and can bind to and inhibit the activities of membrane-type 1 matrix metalloproteinase. These findings implicate that in addition to known receptors for HCV entry, there are still factors involved in the enhancement of cellular uptake of HCV. Moreover, we further define that Disabled-2, an adaptor protein that we found recently as a regulator of clathrin-mediated fibrinogen internalization (Biochim Biophys Acta. 1823:1778-88, 2011), can modulate HCV entry. Our data demonstrate, in addition to concentrate viral particle to cell surface, LDLR may interact with Disabled-2 and facilitate the entry of HCV by clathrin-mediated endocytosis. The data was presented in the 20th International Symposium on Hepatitis C Virus& Related Viruses (Melbourne, Australia, 2013).  

Identifying natural products with anti-HCV or anti-liver fibrosis activity
By the established research platforms for study of HCV, compounds and herbs screening are performed to reveal novel therapy strategy for HCV infection. By collaborating with Dr. SY Wang, we have identified potent natural products with anti-viral activity against HCV. A natural compound pheophytin a extracted from Lonicera hypoglauca Miq. was found to elicit anti-HCV activity and revealed that pheophytin a binds to the active site of HCV-NS3 and inhibits HCV NS3 serine protease activity. Besides, pheophytin a elicits a synergistic anti-HCV activity when in combine use with IFN alpha-2a (Biochem Biophys Res Commun. 385:230-235, 2009). Though the direct-acting antivirals (DAAs) to NS3 protease is approved by FDA for treatment of genotyped 1 patient, the side effects and high cost for treatment remains to be resolved. Effective and abundant nature product from plant could be an alternative way for anti-HCV adjuvant therapy. Hence, by collaborating with Dr. CH Chao, two natural compounds derived from the roots of Flueggea virosa were discovered with anti-HCV activity with no cytotoxicity. The results have been published recently (J Nat Prod.77:22-8, 2014). The detail mechanisms for anti-HCV activity of the two compounds are under investigation.

On the other hand, liver fibrosis is an important pathogenic process during HCV chronic infection. We reported the first evidence-based study to demonstrate that an effective anti-fibrosis Chinese herb regimen modified Yi Guan Jian (mYGJ) decoction induces HSCs apoptosis through ROS accumulation and the intrinsic apoptosis pathway in vitro and in vivo (Evid Based Complement Alternat Med. 2011:459531, 2011 and J Ethnopharmacol. 134:953-60, 2011). These studies provide scientific evidence for Traditional Chinese Medicine (TCM) in treatment fibrosis and establish the platform for us to study HCV-induced liver fibrosis.

Development of molecular diagnostics techniques for detection of infectious pathogen
We developed a method for rapid differentiation of influenza A virus subtypes and genetic screening for virus variants using real-time PCR coupling with high-resolution melting analysis (Journal of Clinical Microbiology 46:1090-1097, 2008). This assay requires no multiplexing or hybridization probes and provides a new approach for influenza A virus subtyping and genetic screening of virus variants in a clinical virology laboratory. In addition, we have combined the power of high-resolution melting analysis and broad-range ribosomal RNA real-time PCR for rapid detection and identification of clinically important bacteria and published our work in the high-ranking journal in laboratory medicine (Clinical Chemistry 52:1997-2004, 2006). This method can detect more than 25 clinically important bacteria through only 1-2 PCR without multiplexing and molecular probe. Hence, this method has greatly enhanced the speed of bacterial species identification in a clinical laboratory setting. This article was selected by the editors and an editorial article from the Journal was written to highlight our work. Recently, we develop a MS-HRM method to detect epigenetic change in oral cancer (Biomed Res Int. 2014:378358.). These techniques are in the transition for clinical applications.


Publication

Selected Publications

  1. Lai ZL, Tsou YA, Fan SR, Tsai MH, Chen HL, Chang NW, Cheng JC*, Chen CM*. Methylation-Associated Gene Silencing of RARB in Areca Carcinogens Induced Mouse Oral Squamous Cell Carcinoma. Biomed Res Int. 2014; 2014:378358.
  2. Chao CH, Cheng JC, Shen DY, Wu TS. Anti-Hepatitis C Virus Dinorditerpenes from the Roots of Flueggea virosa. J Nat Prod. 2014; 24;77(1):22-8.
  3. Chao CH, Cheng JC, Hwang TL, Shen DY, Wu TS. Trinorditerpenes from the roots of Flueggea virosa. Bioorg Med Chem Lett. 2014; 24(2):447-9.
  4. Chu HC, Lee HY, Huang YS, Tseng WL, Yen CJ, Cheng JC*, Tseng CP*. Erythroid differentiation is augmented in Reelin-deficient K562 cells and homozygous reeler mice. FEBS Lett. 2014; 588(1):58-64.
  5. Tseng WL, Chen TH, Huang CC, Huang YH, Yeh CF, Tsai HJ, Lee HY, Kao CY, Lin SW, Liao HR, Cheng JC, Tseng CP. Impaired thrombin generation in reelin-deficient mice: a potential role of plasma reelin in haemostasis. J Thromb Haemost. 2014;12(12):2054-64
  6. Tsai HJ, Huang CL, Chang YW, Huang DY, Lin CC, Cooper JA, Cheng JC, Tseng CP. Disabled-2 Is Required for Efficient Hemostasis and Platelet Activation by Thrombin in Mice. Arterioscler Thromb Vasc Biol. 2014;34(11):2404-12
  7. Chu HC, Tseng WL, Lee HY, Cheng JC, Chang SS, Yung BY, Tseng CP. Distinct effects of Disabled-2 on transferrin uptake in different cell types and culture conditions. Cell Biol Int. 2014;38(11):1252-9.
  8. Fang CP, Li ZC, Yang CH, Cheng JC, Yeh YJ, Sun TH, Li HC, Juang YL, Lo SY. Hepatitis C virus non-structural protein 3 interacts with cytosolic 5'(3')-deoxyribonucleotidase and partially inhibits its activity. PLoS One. 2013;8(7):e68736
  9. Huang JT, Tseng CP, Liao MH, Lu SC, Yeh WZ, Sakamoto N, Chen CM, Cheng JC*. Hepatitis C virus replication is modulated by the interaction of nonstructural protein NS5B and fatty acid synthase. J Virol. 2013; 87(9):4994-5004
  10. Lin JH, Chiu SC, Lin YC, Cheng JC, Wu HS, Salemi M, Liu HF. Exploring the molecular epidemiology and evolutionary dynamics of influenza A virus in Taiwan. PLoS One. 2013; 8(4):e61957.
  11. Cheng JC*, Yeh YJ, Tseng CP, Hsu SD, Chang YL, Sakamoto N, Huang HD. Let-7b is a    
    1. novel regulator of hepatitis C virus replication.Cell Mol Life Sci. 2012; 69(15):2621-33.
  12. Cheng JC, Yeh YJ, Huang YH, Liang KH, Chang ML, Lin CY, Yeh CT. Hepatic expression of MxA and OAS1 in an ex vivo liver slice assay independently predicts treatment outcomes in chronic hepatitis C. J Viral Hepat. 2012; 19(2):e154-62.
  13. Hung WS, Huang CL, Fan JT, Huang DY, Yeh CF, Cheng JC, Tseng CP. The endocytic adaptor protein Disabled-2 is required for cellular uptake of fibrinogen. Biochim Biophys Acta. 2012;1823(10):1778-88
  14. Chen JY, Chen HL, Cheng JC, Lin HJ, Tung YT, Lin CF, Chen CM. A Chinese herbal   medicine, Gexia-Zhuyu Tang (GZT), prevents dimethylnitrosamine -induced liver fibrosis through inhibition of hepatic stellate cells proliferation.J Ethnopharmacol. 2012; 142(3):811-8.
  15. Lin HJ, Tseng CP, Lin CF, Liao MH, Chen CM, Kao ST, Cheng JC*. 2011. A Chinese herbal decoction, modified Yi Guan Jian, induces apoptosis in hepatic stellate cells through a ROS-mediated mitochondrial/caspase pathway. Evid Based Complement Alternat Med.459531. (doi:10.1155/2011/459531)
  16. Lin JH, Chiu SC, Cheng JC, Chang HW, Hsiao KL, Lin YC, Wu HS, Liu HF. 2010. Molecular epidemiology and antigenic analyses of influenza A viruses H3N2 in Taiwan. Clin Microbiol Infect. 17: 214-22
  17. Tseng WL, Huang CL, Chong KY, Liao CH, Stern A, Cheng JC*, Tseng CP*. 2010. Reelin is a platelet protein and functions as a positive regulator of platelet spreading on fibrinogen. Cell Mol Life Sci. 67(4):641-53.
  18. Wang SY, Tseng CP, Tsai KC, Lin CF, Wen CY, Tsay HS, Sakamoto N, Tseng CH, Cheng JC* 2009. Bioactivity-guided screening identifies pheophytin a as a potent anti-hepatitis C virus compound from Lonicera hypoglauca Miq.. Biochem Biophys Res Commun. 385(2):230-5.
  19. Cheng JC, Yeh YJ, Pai LM, Chang ML, and Yeh CT. 2009. 293 Cells Over-expressing Human ADI1 and CD81 are Permissive for Serum-derived Hepatitis C Virus Infection. J Med Virol. 81(9):1560-8
  20. Sung ML, Wu CC, Chang HI, Yen CK, Chen HJ, Cheng JC, Chien S, Chen CN. 2009. Shear stress inhibits homocysteine-induced stromal cell-derived factor-1 expression in endothelial cells. Circ Res. 105(8):755-63.
  21. Lin JH, Tseng CP, Chen YJ, Lin CY, Chang SS, Wu HS, Cheng JC* 2008. Rapid differentiation of influenza A virus subtypes and genetic screening for virus variants by high-resolution melting analysis. J Clin Microbiol. 46:1090-7.
  22. Huang CH, Cheng JC, Chen JC, Tseng CP. 2007 Evaluation of the role of Disabled-2 in nerve growth factor-mediated neurite outgrowth and cellular signalling. Cell Signal. 19:1339-47.
  23. Cheng JC, Huang CL, Lin CC, Chen CC, Chang YC, Chang SS, Tseng CP. 2006. Rapid detection and identification of clinically important bacteria by high- resolution melting analysis after broad-range ribosomal RNA real-time PCR. Clin. Chem. 52:1997-2004
  24. Hsu CW, Cheng JC, Yeh CT. 2006. Quantitative assessment of serum NV-F virus DNA concentrations in samples from patients coinfected with hepatitis B or C virus. J Clin Microbiol. 44:3130-3133.
  25. Huang CL, Cheng JC, Stern A, Hsieh JT, Liao CH, Tseng CP. 2006. Disabled-2 is a novel alphaIIb-integrin-binding protein that negatively regulates platelet-fibrinogen interactions and platelet aggregation. J Cell Sci. 119:4420-30.

▲TOP

Abstract

  1. Cheng JC, Huang CL, Lin CC, Chen CC, Chang YC, Chang SS*, Tseng CP  2007 Rapid detection and Identification of clinically important bacteria by high-resolution melting analysis after broad-range ribosomal RNA real-time PCR. The Annual Meeting of the Society of Laboratory Medicine.(Taipei)
  2. Cheng JC, Liao MH, Liao WS, Eric Han ,Lee YS 2007 A New Application of MALDI Mass Imaging: Direct Analysis of the Cultured Cells The Annual Meeting of Formosan Medical Association. (Taipei)
  3. Huang JT, Tseng CP, Sakanoto Naoya, Lu SC, Chen CM, Cheng JC*. 2008 A novel NS5B-interacting protein modulates hepatitis C virus replication. 15 th International Symposium on Hepatitis C Virus& Related Viruses. (San Antonio, Texas, USA)
  4. Liao MH, Tseng CP, Yu JS, Chen JJ, Cheng JC*. 2008 A novel hepatitis C virus-induced protein modulates hepatic stellate cell activation. 15 th International Symposium on Hepatitis C Virus& Related Viruses. (San Antonio, Texas, USA)
  5. Fan SR, Lai YW, Lin CF, Chang NW, Tsai MH, Chen CM, Cheng JC*. 2009 Identifying   DNA methylation status in oralcancers using CpG island microarray. The 14th Taiwan Joint Cancer Conference (Taipei).
  6. Yeh YJ, Tseng CP, Hsu SD, Chen YJ, Chang YL, Sakamoto N, Huang HD*, Cheng JC*.      2009. Liver-Abundant MicroRNAs Modulate Hepatitis C Virus Gene Expression in HCV Replicon Cells.16th International Symposium on Hepatitis C Virus& Related Viruses.(Nice, France)
  7. Fan SR, Lai YW, Lin CF, Chang NW, Tsai MH, Chen CM, Cheng JC. 2009 Identifying DNA methylation status in oral cancers using CpG island microarray. The 14th Taiwan Joint Cancer Conference, Taipei, Taiwan.
  8. Huang SF, Hsu CS, Chen TT, Cheng JC, Kao MC, Tsai SC. 2009 The expression profiling of microRNA in oral cancer. The 24th joint annual conference of biomedical science, Taipei, Taiwan.
  9. Liu CL, Chang YL, Cheng JC. 2009 Viral gastroenteritis associated with human enteric virus in Mid-Taiwan. 台灣醫事檢驗學會2009年會員代表大會暨學術發表會,台北.
  10. Huang CL, Cheng JC, Lin CC, Tseng CP. 2009 Disabled-2 is a key regulator during mesodermal differentiation and megakaryopoiesis of murine embryonic stem cells. ISTH 2009 - XXII Congress of The International Society on Thrombosis and Haemostasis, Boston, USA.
  11. Huang JL, Liao MH, Chen JJW, Cheng JC. 2010 A novel hepatitis C virus- induced protein modulates hepatic stellate cell contraction. The 25th Joint Annual Conference of Biomedical Science, Taipei, Taiwan.
  12. Lu MH, Tseng CP, Cheng JC. 2010 The involvement of Disabled-2 in Hepatitis C Virus Entry. The 25th Joint Annual Conference of Biomedical Science, Taipei, Taiwan.
  13. Huang CL, Cheng JC, Liu SY, Tseng CP. 2010 Identification of a novel tumor necrosis factor receptor-associated factor 6-binding partner that is a potential lysine-63 linked ubiquitination substrate. The 100th Annual Meeting of the American Association for Cancer Research, Washington DC, USA.
  14. Tseng WL, Chen YY, Cheng JC, Tseng CP. 2010 The interplay between Disabled-2 and protein kinase C epsilon in the regulation of prostate cancer cell survival. The 100th Annual Meeting of the American Association for Cancer Research, Washington DC, USA.
  15. Su KP, Peng CY, Huang SY, Lai HC, Cheng JC, Aitchison KJ. 2010 The effects of polymorphisms in phospholipase a2 and cyclo-oxygenase 2 genes on interferon- alpha-induced depression and polyunsaturated fatty acids levels. The 9th International Society for the Study of Fatty Acids and Lipids (ISSFAL), Maastricht, Netherlands.
  16. Yeh YJ, Tseng CP, Hsu SD, Chang YL, Sakamoto N, Huang HD, Cheng JC. 2010 A liver-abundant miRNA directly targets HCV viral genome and regulates hepatitis C virus RNA accumulation. 17th International Meeting on Hepatitis C Virus and Related Viruses, Yokahama, Japan.
  17. Liao MH, Tseng CP, Cheng-Yuan Peng, Chen JJW, Cheng JC. 2010 A novel hepatitis C virus-induced protein modulates hepatic stellate cell activation through JNK signaling pathway. 17th International Meeting on Hepatitis C Virus and Related Viruses, Yokahama, Japan.
  18. Huang JT, Tseng CP, Naoya Sakamoto, Chen CM, Cheng JC. 2010 The interaction of non-structure protein NS5B and lipogenic enzyme modulates hepatitis C virus replication. 17th International Meeting on Hepatitis C Virus and Related Viruses. Yokahama, Japan.
  19. Cheng JC , Lu MH, Yeh YJ, Lin CF, Tseng CP. 2011 The adaptor protein Disabled-2 mediates hepatitis C virus entry and is a potential target for modulating viral infectivity. 18th International Symposium on Hepatitis C and Related Viruses, Seattle, USA.
  20. Huang CL, Lin CC, Chang YW, Cooper JA, Cheng JC, Tseng C-P. In vivo roles of Disabled-2 (DAB2) in haemostasis and platelet function: studies using a megakaryocyte lineage-restricted DAB2 knockout. The International Society on Thrombosis & Haemostatsis XXIIIrd Congress, Kyoto, Japan, 2011. (Huang CL is the recipient of Young Investigator Award)
  21. Tseng WL, Huang YS, Huang CC, Yeh CF, Chen TH, Cheng JC, Tseng C-P. Specific proteo- lytic cleavage of reelin by coagulation factor X. The International Society on Thrombosis & Haemostatsis XXIIIrd Congress, Kyoto, Japan, 2011. (Tseng WL is the recipient of JSTH Asia-Pacific Scholarship)
  22. Lin HC, Wu MH, Hsu HC, Hsieh CH, Cheng JC, Tseng C-P. A new approach to isolate label-free and viable circulating tumor cells for monitoring cancer patient treatment response. The 102th Annual Meeting of the American Association for Cancer Research, 2012.
  23. Chiang HJ, Cheng JC 2012. A novel cellular protein interacting with HCV NS5B modulates HCV replication. The 25th Joint Annual Conference of Biomedical Science, Taipei, Taiwan.
  24. Cheng JC, Wu TY, Liang PH, Chen YC, Tseng CP. 2012. Novel iminosugar derivatives exhibit potent antiviral activity against hepatitis C virus. 19th International Symposium on Hepatitis C and Related Viruses. Venice, Italy.
  25. Cheng JC, Yeh YJ, Lu MH, Lin CF, Huang HD, Tseng CP. 2013. A novel function of the adaptor protein Disabled-2 in modulating hepatitis C virus entry. 20th International Symposium on Hepatitis C and Related Viruses. Melbourne, Australia.
  26. Cheng JC, Yeh YJ, Huang HD, Tseng CP. 2014. Dual effects of let-7b on the inhibition of HCV infection. 21th International Symposium on Hepatitis C and Related Viruses. Banff, Canada.

▲TOP

Members

  1. Ph D students
    Yeh YJ (葉詠薷)
  2. Master students
    Lai CY (賴君宜)  Li CY (李泉穎)  Huang YC (黃郁淳)
  3. Undergraduate students
    Luo TY (駱子瑜)  Liu YJ (劉羿君)  Chiu HH (邱欣惠)  Ho HN (何欣霓)
  4. Research assistant 
    Chen YW (陳育雯)
  5. Alumni 
    Huang YT (黃裕聰2000-2002, 國光生物科技公司) , Hsieh CS (謝俊生2001-2002, 省立桃園醫院 ), Yang TC (楊長青2000-2002, 長庚基醫所博士, 博士後研究) , Yeh WZ (葉維洲2002-2005, 工研院), Hsiao AL (蕭安旅2000-2002, 中興生醫所, 訊聯生物科技), Shiau CK (蕭丞凱2000-2002, 陽明生化所, 中研院生醫所博班) , Huang JT (黃景堂2000-2015, 中興生科所博士, 服役中), Lin JT (林建宇2000-2003, 陽明遺傳所博班, 進階生物科技) , Liao MH (廖美惠2001-2015, 中興分醫所), Chou HC (周宏真2001-2002, 保誠人壽), Yeh JM (葉郡銘2003-2005, 長庚生統中心), Ku SP (古欣平2002-2004, 中國中醫所研究助理), Chen SS (陳淑幸2003-2005 , 嘉大生科所, 嘉義基督教醫院) , Wang HL (王惠琳2000-2003, 中國癌生所博班), Lin FY (林鳳儀2000-2003, 成大生化所, 衛生局), Chen YF (陳郁芬2005-2007, 中國醫技所), Wu SJ (鄔式绒2001-2004, 台大微免所), Chen YJ (陳嬿如2002-2007, 台大微免所博士, 博士後研究), Lu SC (呂尚潔2003-2006, 中興生醫所, 基隆長庚醫院) , Hong DY (洪端陽2003-2006, 成大醫技所, 為恭醫院) , Liu CY (劉長裕2003-2006, 中國醫技, 泛英醫療器材),  Jan SK (詹勝凱2004-2007, 成大分醫所, 台安醫院) , Wen CY (溫晴雅2004-2007, 陽明生藥所, 送子鳥生殖中心), Wu CL (吳俊龍2005-2008, 長庚生醫所, 基龍米克斯生物科技股份有限公司), Lu MH (盧孟弘2005-2010, 中國醫技所,軟體工程師), Hsieh YW (謝耀文2005-2008, 朝陽生科所, 北極光生物科技有限公司), Yen TH(顏德欣2006-2009, 成大微免所, 愛群婦產科), Chang YC (張原彰2006-2007, 中醫師),  Fan SR (范馨茹2007-2009, 中國醫技所,塑膠工業研究所), Huang JL (黃健倫2007-2010, 朝陽生化所), Lin YC (林詠鈞2007-2010, 朝陽生化所), Su YL (蘇俞綾2008-2010, 中國醫技所, 署立豐原醫院), Peng HH (彭惠萱2008-2011, 美國, 美國醫檢師申請中) , Shih YC (史育慈2008-2011, 國防微免所, 台北市立仁愛醫院), Chang YL (張羽伶2005-2012, 助理, 捷佳科技), Chang HW (張浤偉2009-2011,中國醫技所, 中央研究院生醫所助理), Chiang HZ (姜宏儒2007-2014, 中國醫技所, 服役中), Yang C (楊婕2012-2014, 中國醫技所, 中國研究助理)

▲TOP

Course

Undergraduate courses (大學部)

  • Instrumental analysis (儀器分析)
  • Molecular biology (分子生物學)
  • Biotechnology (生物技術學)
  • Bioinformatics (生物資訊)
  • Clinical virology (臨床病毒學)
  • Molecular diagnosis (醫學分子檢驗)

Graduate courses(研究所)

  • Molecular and cellular biology (細胞分子生物學)
  • Methods in biomedical research (生物醫學研究方法與設計)
  • Special topics on signal transduction and human disease (訊息傳導與疾病)
  • Research methods in medical virology (醫用病毒學研究方法)

 

▲TOP